Vicapsys Life Sciences, Inc. (OTCMKTS:VICP - Get Free Report) shares fell 58.3% during trading on Tuesday . The stock traded as low as $1.25 and last traded at $1.25. 500 shares were traded during trading, an increase of 32% from the average session volume of 380 shares. The stock had previously closed at $3.00.
Vicapsys Life Sciences Stock Performance
The business has a 50-day simple moving average of $1.77 and a two-hundred day simple moving average of $2.05. The company has a market capitalization of $66.36 million, a price-to-earnings ratio of -51.25 and a beta of -3.96.
Vicapsys Life Sciences (OTCMKTS:VICP - Get Free Report) last issued its quarterly earnings results on Friday, January 10th. The company reported ($0.01) earnings per share for the quarter.
About Vicapsys Life Sciences
(
Get Free Report)
Vicapsys Life Sciences, Inc focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers.
Featured Articles
Before you consider Vicapsys Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vicapsys Life Sciences wasn't on the list.
While Vicapsys Life Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
